Lataa...
Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs. This study was designed to evaluate the...
Tallennettuna:
| Julkaisussa: | Pharmaceutics |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6470838/ https://ncbi.nlm.nih.gov/pubmed/30893910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11030133 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|